Delve Bio specializes in advanced metagenomic testing technologies, particularly through its flagship product, Delve Detect. This innovative platform utilizes metagenomic next-generation sequencing (mNGS) to provide comprehensive pathogen detection from a single sample, such as cerebrospinal fluid (CSF). By analyzing both DNA and RNA, Delve Detect can identify a wide array of pathogens—including bacteria, viruses, fungi, and parasites—without the need for prior hypotheses or targeted testing. The system is powered by Delve Decide, a proprietary bioinformatics pipeline that leverages a curated database of over 68,000 unique species, enabling rapid and accurate identification of infectious agents. Results are typically available within 48 hours, significantly reducing the time required for diagnosis compared to traditional microbiological methods.

In addition to its testing capabilities, Delve Bio emphasizes the clinical utility of its mNGS technology, supported by extensive real-world evidence. Studies have shown that mNGS can enhance diagnostic yield, with a notable percentage of infections being identified that standard microbiological tests may miss. The company collaborates with Broad Clinical Labs for sample processing and sequencing, ensuring high-quality genomic analysis. Delve Bio's commitment to actionable diagnostics is further exemplified by its expert medical affairs team, which provides support throughout the testing process, helping healthcare providers make informed decisions based on the results.

United States

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

Delve Bio

Company Details